CirQuest Labs (MLM Medical Labs)

Cygnus Technologies, part of Maravai LifeSciences, is the biopharmaceutical industry’s partner in host cell protein (HCP) and other process-related impurity detection and analytics. In addition, Cygnus now provides innovative viral clearance solutions as well.
Cygnus helps companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release. Cygnus provides analytical tools and solutions delivering insights to improve bioprocess development for faster regulatory approval and better clinical outcomes.
Cygnus is an industry pioneer responsible for developing and commercializing the first generic assay kits for HCP detection. Its reputation for quality is recognized by the industry and global regulatory agencies. It continues to advance the science of bioprocess impurity detection with new breakthroughs, including its Antibody Affinity Extraction™ (AAE) technology and orthogonal methods of HCP analysis that integrate Mass Spectrometry, AAE and ELISA. To reduce the cost and risk associated with viral clearance studies, Cygnus also offers a unique approach that utilizes non-infectious mock virus particles through its MockV™ virus clearance kits.
Cygnus’ proprietary technology, available through its off-the-shelf and custom analytics programs, sets the gold standard for enabling HCP and other bioprocess impurity antibody assays. Cygnus delivers best-in-class customer service and technical expertise, operational excellence and ISO-9001:2015 certified quality management systems.
Founded by Ken Hoffman in 1997, Cygnus continues to support and advance technology in order to improve biotherapeutic safety and accelerate the movement of new therapeutics through the development and regulatory approval process.
Located in Southport, North Carolina, Cygnus Technologies is online at www.cygnustechnologies.com.

PharmOptima™, a member of Genesis Biotechnology Group® (GBG), has been advancing drug discovery and development in various therapeutic areas and has filled a niche in ocular drug development since 2003. PharmOptima’s in vivo services include studies in the fields of drug absorption, distribution, metabolism, and excretion (ADME), pharmacokinetics (PK), and pharmacology. It provides liquid chromatography and mass spectrometry (LC-MS/MS) bioanalysis in support of discovery and development programs, including method development and validation in accordance with regulatory guidelines. Its biochemistry expertise allows them to assess the role of biomarkers in numerous disease models. PharmOptima’s biochemical capabilities include in vitro and cell based assay development for compound profiling as well as protein cloning and expression. Its expertise extends to the custom development of enzyme-linked immunosorbent assays (ELISA) and electrochemiluminescence multiplex formats.

Signum Dermalogix, a spin out of Signum Biosciences, is a private biotech company founded in 2011 from technologies developed by Dr. Jeffry Stock at Princeton University. We develop cosmetic functional ingredients as well as topical drug candidates for dermatological disease. Our main research focus is to produce novel chemical entities and botanical extracts for skin care by performing robust screening assays in our labs. In addition we provide in vitro and in vivo assay systems and robust analytical expertise including safety, efficacy and claim substantiation for cosmetics, botanicals, nutraceuticals and pharmaceuticals. We specialize in producing customized cosmetic claim support and/or efficacy tests providing robust scientific data to support advertising or packaging claims. Signum Biosciences is focused on cutting edge research in neurodegeneration, while Signum Dermalogix provides innovation in cosmetics, therapeutic dermatology and testing services. We are a company focused on the discovery and development of innovative products to address major medical needs in the field of dermatology. Signum Dermalogix develops synthetic compounds that are mimetics of natural lipid ligands crucial to cellular regulation and signaling. These proprietary New Chemical Entities (NCEs) have significant pharmaceutical potential for treating regulatory dysfunctions underlying inflammatory skin diseases such as Acne, Atopic Dermatitis, Psoriasis, and Rosacea.

Amarex is a global, full-service Contract Research Organization (CRO), whose leadership team has significant expertise conducting biomedical research, and whose combined experience includes the design and conduct of several hundred clinical research projects in many therapeutic indications. Amarex provides comprehensive services in Project Management (Phase I-IV, BE/BA, PK/PD), Regulatory Affairs (FDA Applications and meetings, Applications to International Health Authorities, GxP Compliance Audits), Clinical Operations, Adaptive Study Designs, Statistical Analysis, Data Management, Medical Monitoring, Safety and Pharmacovigilance, and General Consulting. Amarex can take your product through the entire approval process, from creating the regulatory approval strategy, to conducting trials, to writing the marketing approval application. Join our growing list of clients with approved products. Amarex provides high quality and cost efficient services.

Sign-up to receive invites to webinars, training courses and the latest cutting-edge information on clinical trials: https://go.pardot.com/l/129231/2020-07-27/39ng9k

BioFortis is a leading provider of precision medicine software solutions. Its flagship product, Labmatrix, is a web-based database application that addresses the needs in clinical trial sample and consent tracking, study subject and biospecimen management, and collaborative clinical & translational research programs.

With enterprise-grade capabilities for importing, integrating, and access controlling multiple eClinical and bioresearch data collections in a tightly-linked and regulatory-compliant manner, Labmatrix further empowers its users to easily ask sophisticated questions and generate scientific insights/reports, thus breaking down the technical barriers to big & complex data access and exploration.